Figure S1. CONSORT diagram. aCrossed over to receive single-agent ibrutinib after PD (n = 35). bOf the 29 patients in the placebo-rituximab arm who discontinued treatment due to investigator decision, 24 patients discontinued due to study unblinding per Data Monitoring Committee recommendation. cDiscontinued rituximab before the completion of 8 infusions. Figure S2. Progression-free survival benefit across prespecified subgroups by prior treatment status. CI, confidence interval; IgG, immunoglobulin G; Hgb, hemoglobin; HR, hazard ratio; RTX, rituximab; IPSSWM, International Prognostic Scoring System for Waldenström’s Macroglobulinemia. Figure S3. Serum immunoglobulin M (IgM) improvement over time. Figure S4. Overall survival. Not censored at crossover. aCounterfactual survival times in crossover patients (n = 35) were calculated using the two-stage Accelerated Failure Time model (Latimer NR, et al: Med Decis Mak. 2014;34(3):387-402). CI, confidence interval; HR, hazard ratio. TABLE S1. Baseline Demographics and Clinical Characteristics by Genotype TABLE S2. Reasons for Ibrutinib Discontinuation. TABLE S3. Key Concomitant Medications of Interest TABLE S4. Adverse events leading to ibrutinib dose reductions.

Peer reviewed